On Friday, Shares of Lowe’s Companies, Inc. (NYSE:LOW), lost -0.67% to $69.98.
At its annual meeting of shareholders, Lowe’s Companies, Chairman, President and CEO Robert A. Niblock informed shareholders that planned investments focused on finding new ways to connect and serve customers began to take hold in 2014, enabling the company to deliver strong financial performance for the year.
Niblock highlighted the company’s continued focus on developing its omni-channel retail capabilities, ensuring Lowe’s meets customer needs whenever and wherever they choose to engage with the company – in store, in home and on the job, online and through contact centers. The company is also focused on further building customer experience design capabilities that differentiate Lowe’s from other home improvement providers, improving its offering for Pro customers and ongoing to improve productivity and profitability.
Lowe’s Companies, Inc. operates as a home improvement retailer. The company offers products for maintenance, repair, remodeling, and home decorating.
Shares of Peregrine Pharmaceuticals (NASDAQ:PPHM), inclined 5.22% to $ 1.41, during its last trading session.
Peregrine Pharmaceuticals, declared that the company has reached a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSK) to explore the potential of Peregrine’s proprietary phosphatidylserine (PS)-targeting antibody platform. The aim of the research is to identify effective treatment combinations based on Peregrine’s PS-targeting agents, counting Peregrine’s lead clinical agent bavituximab, with other checkpoint inhibitors or immune stimulating agents that will further guide the bavituximab clinical development program.
The studies at MSK will be performed under the direction of Taha Merghoub, Ph.D., Associate Attending Biologist, Melanoma and Immunotherapeutics Service, Ludwig Collaborative and the Swim Across America Laboratory, a part of the laboratory of Jedd D. Wolchok, M.D., Ph.D., a leader in the field of cancer immunotherapy. Dr. Wolchok serves as the Chief, Melanoma and Immunotherapeutics Service, Lloyd J. Old Chair for Clinical Investigation in addition to an Associate Director of the Ludwig Center for Cancer Immunotherapy at MSK.
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States.
At the end of Friday’s trade, Shares of Vascular Biogenics Ltd (NASDAQ:VBLT), gained 9.08% to $ 8.05.
Vascular Biogenics, declared positive interim results from an investigator-initiated, Phase 1/2a trial of multiple dose VB-111 in recurrent platinum-resistant Mullerian cancer. The data demonstrated promising evidence of clinical benefit in patients with recurrent platinum-resistant Mullerian cancer who received VB-111 in conjunction with weekly paclitaxel. These study results were presented at the 2015 American Society of Clinical Oncology Annual Meeting on Saturday, May 30, 2015 in S Hall A at the McCormick Place Convention Center in Chicago, Illinois.
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases in Israel.
Finally, Ally Financial Inc (NYSE:ALLY), ended its last trade with -0.35% loss, and close at $ 22.67.
Ally Financial, declared the early results of its formerly declared cash tender offers to purchase, following the terms and conditions as described in an Offer to Purchase, dated May 14, 2015, and related Letter of Transmittal, up to $700,000,000 aggregate principal amount of the following series of notes issued by Ally:
- 000% Senior Guaranteed Notes due 2020 (the “8.000% Senior Guaranteed Notes” or “Priority 1 Notes”);
- 500% Senior Guaranteed Notes due 2020 (the “7.500% Senior Guaranteed Notes” or ” Priority 2 Notes”);
- 000% Senior Notes due 2031 (the “2031 Notes” or ” Priority 3 Notes”), offered that Ally will accept for purchase no more than $150,000,000 aggregate principal amount of 2031 Notes in the Tender Offers (subject to enhance by Ally, the “Tender Cap”);
- 500% Senior Guaranteed Notes due 2017 (the “5.500% Senior Guaranteed Notes”); and
- 250% Senior Guaranteed Notes due 2017 (the “6.250% Senior Guaranteed Notes” and, together with the 5.500% Senior Guaranteed Notes, the ” Priority 4 Notes”)
Ally Financial Inc. provides financial products and services primarily to automotive dealers and their customers in the United States. It offers dealer financial services, counting a range of financial services and insurance products to automotive dealers and retail customers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
